Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,071

Document Document Title
WO/2020/186961A1
Disclosed in the present invention are a bulleyaconitine D crystal and a preparation method therefor. Figure 1 shows an X-ray powder diffraction spectrum of the crystal according to the present invention, the spectrum being measured with...  
WO/2020/186960A1
A bulleyaconitine A crystalline form C, and a preparation method therefor. An X-ray powder diffraction spectrum of the crystalline obtained by measurement using a Cu-Kα ray is as shown in fig. 1. The preparation method therefor comprise...  
WO/2020/186962A1
Provided is a crystal form E of bulleyaconitine A and a preparation method for the crystal form E of bulleyaconitine A. An X-ray powder diffraction spectrum of the crystal form measured by Cu-K α-ray is as shown in FIG. 1. The crystal f...  
WO/2020/186963A1
Crystal form G of bulleyaconitine A and a preparation method therefor. Crystal form G of bulleyaconitine A was prepared by adding bulleyaconitine A to a mixed solution of methanoic acid and n-heptane and dissolving, stirring at a low tem...  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/184649A1
Provided as a material able to produce an optical member, such as a lens having a high light transmittance, is a solvate of a compound represented by general formula 1, wherein the solvent contains a nitrogen atom-containing organic comp...  
WO/2020/169648A1
The present invention relates to compounds of Formula (I), 5 wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controll...  
WO/2020/165233A1
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for contro...  
WO/2020/165102A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...  
WO/2020/160134A1
Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by i...  
WO/2020/124688A9
Provided in the present invention are full-spectrum high-brightness and high-stability fluorescent dyes, the dyes being one or several of the following mixed according to any ratio: 4-amido substituted naphthalimide dye, bisalkoxy substi...  
WO/2020/139971A3
The present disclosure provides methods of preparing Compound of Formula (I), solid state forms of the same and compositions comprising the same. Also disclosed herein are methods of preparing a diacetate salt of Compound of Formula (I) ...  
WO/2019/226678A3
Disclosed herein are compound capable of exploiting non-bonding electron densities, for example, cationic open-shell, pi-conjugated bisphenalenyls wherein intermolecular covalent bonding interactions can occur in multiple dimensions. Fur...  
WO/2020/143198A1
Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used ...  
WO/2020/139291A1
The present patent application discloses naphthalimide derivatives and in particular e.g. N-aryl-substituted naphthalimidopropylamine derivatives (i.e. 2-[3-(amino)propyl]-1H-benz[de]isoquinoline-1,3(2H)- dione derivatives) such as e.g. ...  
WO/2020/136188A1
The present invention relates to a process for the preparation of a compound (I) or pharmaceutically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and treatment of a disea...  
WO/2020/139971A2
The present disclosure provides methods of preparing Compound of Formula (I), solid state forms of the same and compositions comprising the same. Also disclosed herein are methods of preparing a diacetate salt of Compound of Formula (I) ...  
WO/2020/130152A1
The present invention relates to compounds of formula I bearing a sulfoxonium ylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detect...  
WO/2020/124688A1
Provided in the present invention are full-spectrum high-brightness and high-stability fluorescent dyes, the dyes being one or several of the following mixed according to any ratio: 4-amido substituted naphthalimide dye, bisalkoxy substi...  
WO/2020/125640A1
Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for...  
WO/2020/132653A1
The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and ce...  
WO/2020/125580A1
An impurity A, an impurity B, and an impurity C and preparation methods therefor, and an application as a reference standard for quality control of a compound as represented by formula VI.  
WO/2020/111140A1
Provided are a novel fused ring compound that exhibits excellent charge transport capacity, a production method therefor, and an organic EL element material containing said compound. This fused ring compound has a specific structure and ...  
WO/2020/103945A1
Disclosed are an oxycodone compound, and an intermediate and a preparation method therefor. Specifically disclosed is a preparation method for a compound represented by formula A9, comprising the following steps: under a protective gas, ...  
WO/2020/105364A1
The purpose of the present invention is to provide a non-ionic photo-acid generator which exhibits high photosensitivity to i-rays, excellent compatibility with, and solubility in, a resist solution, and excellent thermal stability. The ...  
WO/2020/103294A1
Disclosed are an organic micromolecule light-emitting material and an organic electroluminescent component. The organic micromolecule light-emitting material is produced by coupling a novel acridine donor unit 10H-spiro[acridine-9,2'-ada...  
WO/2020/102576A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/102096A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/102574A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/023700A3
Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as Topl and / or Tdpl inhibitors. The disclosure provides pharmaceutical compositions containing a co...  
WO/2020/081975A1
The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H- dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding of Cu/Zn Superoxide Dismutase (SOD1) or mediated by astrocyte toxicity aff...  
WO/2020/077217A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.  
WO/2020/075761A1
The present invention addresses the problem of providing: an imide derivative which has a high luminous quantum yield and in which concentration quenching is suppressed; a luminous composition containing the same; a luminous thin film; a...  
WO/2020/069179A1
The present invention provides a method for chemically modifying a nucleic acid molecule using sulfinate reagents to increase stability in vitro and in vivo. Screening methods for nucleobase modifications that reduce cleavage of a nuclei...  
WO/2019/078968A3
The present disclosure describes novel IDO inhibitors and methods for preparing them. The pharmaceutical compositions comprising such IDO inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders ...  
WO/2020/063760A1
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.  
WO/2019/132492A9
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting device comprising the same.  
WO/2020/050160A1
A hydrogenation catalyst for amide compounds which comprises hydroxyapatite and, fixed thereto, platinum and vanadium, characterized in that 15-80% of the surface of the platinum is covered with vanadium. With the catalyst, it is possibl...  
WO/2020/050729A1
The invention relates to a radioisotope-labelled compound of quaternary ammonium salt of a polycyclic aromatic amine with formula I, wherein the wavy line indicates a single bond between the non-nodal carbon atom of a polycyclic aromatic...  
WO/2020/047168A1
The present invention is directed towards new chemical entities winch primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, pa...  
WO/2020/036329A1
The present invention relates to a fluorescent probe for detecting NAD(P)H in mitochondria, and a detection method using same. A probe of the present invention exhibits high selectivity and sensitivity to NAD(P)H and emits strong red flu...  
WO/2020/023391A1
The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceut...  
WO/2020/016264A1
The present invention relates to compounds of the formula (1) and mixture comprising these compounds, which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which com...  
WO/2020/016233A1
The present invention relates to an organic compound of formula (1), suitable for use as a layer material for electronic devices, and it relates to an organic semiconductor layer comprising at least one compound thereof, as well as to an...  
WO/2020/011228A1
Antibiotic compounds having both antibiotic and aggregation-induced emission (AIE) characteristics. The compounds comprise an azole antibiotic unit, for example naphthalimide triazole (NT), and an AIE unit, for example triphenylethylene ...  
WO/2020/012842A1
The present invention provides a photoelectric conversion element which is capable of improving the afterimage characteristics. This photoelectric conversion element is provided with: a first electrode and a second electrode, which are a...  
WO/2020/010143A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to tre...  
WO/2019/210332A3
Some embodiments provided herein relate to methods and compositions for reducing the risk of relapse of a hyperproliferative disorder, such as acute myeloid leukemia (AML), in a subject in which the hyperproliferative cells of the subjec...  
WO/2019/222854A1
Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine- containing ligand frameworks capable of anchoring to Pt via more than one bindin...  
WO/2019/222103A1
The invention is directed to a novel crystalline S-apomorphine hydrochloride hydrate salt.  

Matches 1 - 50 out of 6,071